Interleukin-2 Production During Intravesical Bacille Calmette-Guerin Therapy for Bladder Cancer

Overview

Journal Clin Immunol Immunopathol

Specialty Allergy & Immunology

Date 1986 Aug 1

PMID 3487405

Citations 12

Authors

T L Ratliff

E O Haaff

W J Catalona

Affiliations

Soon will be listed here.

Abstract

Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.

Citing Articles

Nonmuscle invasive bladder cancer: a primer on immunotherapy.

Maruf M, Brancato S, Agarwal P Cancer Biol Med. 2016; 13(2):194-205.

PMID: 27458527 PMC: 4944546. DOI: 10.20892/j.issn.2095-3941.2016.0020.

Evolving immunotherapy strategies in urothelial cancer.

Brancato S, Lewi K, Agarwal P Am Soc Clin Oncol Educ Book. 2015; :e284-90.

PMID: 25993187 PMC: 4903167. DOI: 10.14694/EdBook_AM.2015.35.e284.

Bladder Cancer Immunotherapy: BCG and Beyond.

Askeland E, Newton M, ODonnell M, Luo Y Adv Urol. 2012; 2012:181987.

PMID: 22778725 PMC: 3388311. DOI: 10.1155/2012/181987.

Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.

Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S Cancer Immunol Immunother. 2003; 52(8):481-6.

PMID: 12707736 PMC: 11032925. DOI: 10.1007/s00262-003-0384-9.

Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.

Haley J, Young D, Alexandroff A, JAMES K, Jackson A Immunology. 1999; 96(1):114-21.

PMID: 10233685 PMC: 2326725. DOI: 10.1046/j.1365-2567.1999.00667.x.